Comparison · NCT02566369-sae
CD5789 (Trifarotene) 50μg/g Cream vs Placebo Cream: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CD5789 (Trifarotene) 50μg/g Cream vs Placebo Cream: serious adverse events. Trial comparisons, record NCT02566369-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02566369-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00654 | 0.00254 | 0.0167 | wilson | |
| Risk in group 2 | 0.00336 | 0.000921 | 0.0122 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00318 | -0.00648 | 0.0136 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.95 | 0.358 | 10.6 | log | |
| Odds ratio, group 1 over group 2 | 1.95 | 0.357 | 10.7 | log | |
| Number needed to harm, for one more participant with a serious adverse event on CD5789 (Trifarotene) 50μg/g Cream than on Placebo Cream | 314 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CD5789 (Trifarotene) 50μg/g Cream | CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks. | 4 | 612 | EG000 |
| Group 2 | Placebo Cream | Placebo cream applied once daily for 12 weeks | 2 | 596 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Each participant's adverse events were collected starting at the first visit (screening) until the last visit (Week 12).
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
- NCT number
- NCT02566369
- Phases
- PHASE3
- Conditions
- Acne Vulgaris
- Interventions
- CD5789 (trifarotene) 50μg/g cream, Placebo cream
- Lead sponsor
- Galderma R&D
- Results first posted
- 2019-08-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02566369?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02566369-sae